The receptor binding characteristics and biologic potency of biosynthetic human proinsulin (rDNA) were determined in isolated rat adipocytes and compared with those of insulin. In competition with 125I(A14)-iodoinsulin for binding to adipocyte receptors at 15°C, proinsulin showed a 100-fold lower affinity for binding than did insulin. A proinsulin concentration of 3.2 ± 0.8 × 10−7 M was required for 50% inhibition of tracer binding as compared with a concentration of 1.7 ± 0.3 × 10−9 M for insulin. These results were confirmed in direct competition studies using proinsulin and 125I-iodoproinsulin. A similar 100-fold difference was also observed in competitive binding experiments conducted at 37°C. The biologic potency of human proinsulin was evaluated by its ability to stimulate glucose incorporation into total fat cell lipid and also by its antilipolytic activity. Glucose incorporation into lipid was half-maximal at a proinsulin concentration of 1.5 ± 0.4 × 10−8 M, whereas the same response was observed at an insulin concentration of 5.2 ± 1 × 10−11 M. Proinsulin also demonstrated an antilipolytic potency that was <1% that of insulin. The time course over which insulin and proinsulin stimulated glucose incorporation into lipid was the same, as was the time course over which the stimulation dissipated after removal of the hormones. No synergism of insulin and proinsulin stimulation of lipogenesis was observed when fat cells were incubated with submaximal concentrations of the two hormones. It is concluded that biosynthetic human proinsulin has approximately 1% the receptor binding affinity and biologic potency of insulin in the isolated rat adipocyte system.
Skip Nav Destination
Article navigation
Original Contributions|
November 01 1984
In Vitro Activity of Biosynthetic Human Proinsulin: Receptor Binding and Biologic Potency of Proinsulin and Insulin in Isolated Rat Adipocytes
Daniel E Peavy;
Daniel E Peavy
Veterans Administration Medical Center and Departments of Physiology and Medicine, Indiana University School of Medicine, and the Lilly Research Laboratories, a division of Eli Lilly and Company
Indianapolis, Indiana
Search for other works by this author on:
Jill D Abram;
Jill D Abram
Veterans Administration Medical Center and Departments of Physiology and Medicine, Indiana University School of Medicine, and the Lilly Research Laboratories, a division of Eli Lilly and Company
Indianapolis, Indiana
Search for other works by this author on:
Bruce H Frank;
Bruce H Frank
Veterans Administration Medical Center and Departments of Physiology and Medicine, Indiana University School of Medicine, and the Lilly Research Laboratories, a division of Eli Lilly and Company
Indianapolis, Indiana
Search for other works by this author on:
William C Duckworth
William C Duckworth
Veterans Administration Medical Center and Departments of Physiology and Medicine, Indiana University School of Medicine, and the Lilly Research Laboratories, a division of Eli Lilly and Company
Indianapolis, Indiana
Search for other works by this author on:
Address reprint requests to Daniel E. Peavy, Ph.D., Endocrinology Section (111E), Veterans Administration Medical Center, 1481 West 10th Street, Indianapolis, Indiana 46202.
Diabetes 1984;33(11):1062–1067
Article history
Received:
January 16 1984
Revision Received:
April 26 1984
Accepted:
April 26 1984
PubMed:
6389225
Citation
Daniel E Peavy, Jill D Abram, Bruce H Frank, William C Duckworth; In Vitro Activity of Biosynthetic Human Proinsulin: Receptor Binding and Biologic Potency of Proinsulin and Insulin in Isolated Rat Adipocytes. Diabetes 1 November 1984; 33 (11): 1062–1067. https://doi.org/10.2337/diab.33.11.1062
Download citation file:
34
Views